This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Welcome to Reed Smith's viewpoints — timely commentary from our lawyers on topics relevant to your business and wider industry. Browse to see the latest news and subscribe to receive updates on topics that matter to you, directly to your mailbox.
| 1 minute read

CMS proposes delay in start of Medicare radiation oncology payment innovation model

The Centers for Medicare & Medicaid Services has announced that it proposes to delay the start date of a new Radiation Oncology (RO) innovation model (RO Model) that would be in effect today had Congress not acted twice to delay its implementation. The RO Model would test prospective site-neutral, episode-based payments to Medicare reimbursement for radiotherapy (RT) care on an episode of care basis to hospital outpatient departments, physician group practices, and freestanding radiation therapy centers.  CMS has hoped that the RO Model could reduce Medicare expenditures for RT services while preserving or enhancing the quality of care for Medicare beneficiaries. 

In September 2020, CMS published a final rule to launch the RO Model with a model performance period that was to begin on January 1, 2021, later delayed to begin on July 1, 2021, and to end on December 31, 2025, giving RO participants an additional 6 months to prepare for the RO Model. The Consolidated Appropriations Act (CAA), 2021 - enacted by Congress in December 2020 - included a provision that prohibited implementation of the RO Model before January 1, 2022. Then, in December of 2021, Congress further prohibited implementation of the RO Model prior to January 1, 2023, through a provision of the Protecting Medicare and American Farmers from Sequester Cuts Act. 

Stakeholders in the radiation oncology provider community have expressed concerns that the model did not strike the right balance between offering incentives to providers to participate and the anticipated reductions in payment rates for radiation oncology services. As the model developed, RO participants and stakeholders requested changes to the RO Model’s payment methodology and to other aspects of the RO Model design and participation requirements, but many stakeholders believed the concerns and recommendations were never adequately incorporated into the RO Model.

In announcing the delay, CMS acknowledged that some stakeholders will not support the RO Model test moving forward with unchanged discounts. CMS further acknowledges that many stakeholders oppose any increase in the geographic scope of the current Model.

Because of the ongoing uncertainty over the RO model, CMS is proposing to amend the rule to establish that the start and end dates for the RO model will come only through future rulemaking, which CMS announces will also involve modifications to the model design.

The proposed rule is unpublished and expected to be published in the Federal Register next week. Comments on the proposed rule will be considered by CMS if received no later than 60 days after the date of publication in the Federal Register.

There is a substantial cost to continue funding preparation for implementation of the RO Model in 2023.


health care & life sciences, radiation oncology, cms, medicare